Key result
Four patients developed torsade de pointes after receiving conventional doses of disopyramide phosphate (600 mg/day) for recurrent atrial fibrillation.
Why the study?
Does disopyramide phosphate induce torsade de pointes in patients with recurrent atrial fibrillation?
Case Report (n=4)
No
Does disopyramide phosphate induce torsade de pointes in patients with recurrent atrial fibrillation?
Disopyramide therapy can induce torsade de pointes, a risk that may be heightened when used in combination with other QT interval-prolonging agents like amiodarone or in patients with severe repolarization delay.
No takes yet. Share an insight, caveat, or question.
Disopyramide may provoke torsade de pointes; leaves open arrhythmia risk with amiodarone combinations.
Dan Tzivoni (1981) conducted a case report in Recurrent atrial fibrillation (n=4). Disopyramide phosphate was evaluated on Ventricular tachycardia (torsade de pointes). Four patients developed torsade de pointes after receiving conventional doses of disopyramide phosphate (600 mg/day) for recurrent atrial fibrillation.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: